Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...

May 17, 2021

Developments

Arctic Vision in exclusive licensing pact with ActualEyes

Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...

May 14, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Developments

IntelGenx expands psychedelics accord with atai

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...

May 12, 2021

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

IntelGenx shareholders approve atai Life Sciences investment

Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...

May 11, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Developments

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) completed recruitment for its Phase 2a AMBITION clinical trial, with all non-alcoholic steatohepatitis (NASH) patients in the 225 mg CRV431 dosing cohort now enrolled. After...

May 6, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received a positive opinion on European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the EMA committee for orphan medicinal products. The positive...

April 20, 2021

Developments

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

The first patient has been treated in Ripple Therapeutics’ RIPPLE-1 Phase 2 trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases. RIPPLE-1 is a single...

April 20, 2021

Developments

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

MiMedx Group (NASDAQ:MDXG) announced that the last patients have completed their last clinical visits in two late-stage IND trials: Phase 3 studies of AmnioFix injectable as a potential treatment for plantar fasciitis...

April 19, 2021

Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

The FDA’s Circulatory Systems Device Advisory Panel issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Heart System to the FDA’s Office of Health Technology 2 (Cardiovascular...

April 7, 2021

Developments

IntelGenx ships first CBD filmstrip order to Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) completed its first shipment, consisting of 75,000 CBD filmstrips, to Heritage Cannabis Holdings (CSE:CANN) for the Canadian and Australian markets. The CBD filmstrips were produced at...

April 1, 2021

Developments

111, Inc., Jianming Pharma to develop chronic disease management platform in China

111, Inc. (NASDAQ:YI), a leading digital healthcare platform company in China, and Jianming Pharmaceutical Group signed a strategic cooperation agreement to develop an online chronic disease management platform for the...

March 25, 2021

Developments

Lineage presents additional interim data with OpRegen in dry AMD with GA

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) presented new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, for the treatment of dry age...

March 23, 2021

Developments

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results from an in vivo study of CRV431 in a diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND). Hepion’s CRV431 administered orally and once...

March 23, 2021

Developments

Diabeloop, BIOCORP in personalized diabetes management pact

Diabeloop and BIOCORP (FR0012788065 – ALCOR) are collaborating to offer new, simple and personalized treatment options to people living with diabetes. BIOCORP has developed and markets Mallya, an intelligent sensor for...

March 22, 2021

Developments

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Shanghai-based 111 Inc. (NASDAQ:YI) reported net revenue of $405.1-million (U.S.) in the fourth quarter of 2020, which was up 96.1%, from the year earlier quarter, beating its previous guidance of 81% to 90% growth. Net...

March 18, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Developments

111, Inc. in strategic partnership with BeiGene

111, Inc. (NASDAQ:YI), a leading digital healthcare platform in China, entered into a strategic cooperation agreement with BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage and development biotechnology company...

March 17, 2021

Developments

111, Inc. achieves full distribution coverage across mainland China

111, Inc. (NASDAQ:YI) opened two new state-of-the-art, technology-driven fulfillment centers in the Northern cities of Xi’an and Shenyang, bringing the company’s total number of fulfillment centers to eight. The...

March 16, 2021

Subscribe